Gastrointestinal Pharmacology

Correct Answer

D — Prednisolone

Rationale

Prednisolone is classified as a synthetic glucocorticoid and is the primary pharmacological treatment for severe alcoholic hepatitis meeting the Maddrey discriminant function threshold. Pentoxifylline is a phosphodiesterase inhibitor. N-acetylcysteine is a glutathione precursor. Rifaximin is a minimally absorbed rifamycin antibiotic used for hepatic encephalopathy prophylaxis.

Correct Answer

B — Ursodeoxycholic acid

Rationale

Ursodeoxycholic acid is classified as a hydrophilic bile acid. Obeticholic acid is a farnesoid X receptor agonist. Resmetirom is a thyroid hormone receptor-beta agonist. Rifaximin is a minimally absorbed rifamycin antibiotic.

Correct Answer

A — Farnesoid X receptor

Rationale

Obeticholic acid is classified as a farnesoid X receptor (FXR) agonist. Resmetirom is a thyroid hormone receptor-beta agonist. Pioglitazone is a PPAR-gamma agonist. Prednisolone acts through the glucocorticoid receptor.

Correct Answer

C — Lactulose

Rationale

Lactulose is classified as a non-absorbable disaccharide. Rifaximin is a minimally absorbed rifamycin antibiotic. Neomycin is an aminoglycoside antibiotic. Ursodeoxycholic acid is a hydrophilic bile acid used for primary biliary cholangitis.

Correct Answer

D — Thyroid hormone receptor-beta

Rationale

Resmetirom is classified as a thyroid hormone receptor-beta (THR-beta) agonist — the first drug approved specifically for MASH. Obeticholic acid is an FXR agonist. Fenofibrate acts through PPAR-alpha. Semaglutide and liraglutide are GLP-1 receptor agonists.

Correct Answer

A — Minimally absorbed rifamycin antibiotic

Rationale

Rifaximin is classified as a minimally absorbed rifamycin antibiotic with less than 0.4% systemic bioavailability. Norfloxacin is a fluoroquinolone used for SBP prophylaxis. Neomycin is a non-absorbable aminoglycoside. Clarithromycin and erythromycin are macrolides with distinct indications.

Correct Answer

B — Prednisolone suppresses the hepatic inflammatory cytokine cascade — particularly TNF-alpha and IL-8 — through broad genomic glucocorticoid receptor-mediated suppression of pro-inflammatory gene transcription

Rationale

Severe alcoholic hepatitis is characterized by massive hepatic inflammatory injury driven by cytokine release — predominantly TNF-alpha and IL-8 — from activated Kupffer cells and recruited neutrophils in response to alcohol-induced hepatocyte damage. Prednisolone, acting through the glucocorticoid receptor, translocates to the nucleus and suppresses transcription of pro-inflammatory genes including those encoding TNF-alpha, IL-8, IL-1, and adhesion molecules. This broad cytokine suppression reduces hepatocyte apoptosis and necrosis, producing the 28-day mortality benefit demonstrated in meta-analyses. However, as the STOPAH trial confirmed, this benefit is not maintained at 90 days or 1 year — prednisolone improves early survival without altering the underlying disease trajectory or preventing long-term complications of alcoholic liver disease. Active infection must be excluded before starting prednisolone, as immunosuppression in the presence of sepsis worsens outcomes substantially.

Correct Answer

C — The STOPAH trial demonstrated that pentoxifylline had no significant effect on 28-day, 90-day, or 1-year mortality compared with placebo

Rationale

Pentoxifylline is a phosphodiesterase inhibitor that reduces TNF-alpha production and was previously used as an alternative to prednisolone when corticosteroids were contraindicated, based on earlier data suggesting reduced hepatorenal syndrome risk. The STOPAH (Steroids or Pentoxifylline for Alcoholic Hepatitis) trial — the largest randomized controlled trial in severe alcoholic hepatitis — definitively addressed this question: pentoxifylline produced no significant reduction in 28-day, 90-day, or 1-year mortality compared with placebo. It is no longer recommended for this indication. Prednisolone demonstrated a 28-day mortality benefit in STOPAH, though this benefit was not sustained at 90 days or 1 year. Pentoxifylline's mechanism — phosphodiesterase inhibition reducing TNF-alpha — does not translate to clinically meaningful survival benefit in severe alcoholic hepatitis.

Correct Answer

C — Obeticholic acid is itself a bile acid analogue; elevated circulating bile acids activate itch-sensing neurons in the skin

Rationale

Pruritus is the most important adverse effect limiting obeticholic acid use, occurring in the majority of patients. Obeticholic acid is a potent bile acid analogue; as an FXR agonist it modulates bile acid metabolism, and the resulting changes in circulating bile acid profiles contribute to pruritogenic signaling. Elevated bile acids in cholestatic disease already cause pruritus through activation of TGR5 receptors and Mas-related G protein-coupled receptors (MRGPRs) on cutaneous itch-sensing neurons; obeticholic acid can intensify this signal. Management of obeticholic acid-induced pruritus includes cholestyramine (bile acid sequestrant) or rifampicin as antipruritic agents, and dose titration starting at 5 mg rather than jumping immediately to 10 mg. Obeticholic acid is contraindicated in decompensated cirrhosis (Child-Pugh B or C) because it can worsen hepatic function in this setting — but this is a separate contraindication from the pruritus adverse effect, not its explanation.

Correct Answer

A — Accelerated colonic transit reduces the contact time between gut bacteria and nitrogenous substrates, limiting the total amount of ammonia generated before it can be trapped or expelled

Rationale

Lactulose reduces systemic ammonia through two complementary mechanisms. The primary mechanism is the acid-trapping effect: fermentation to organic acids lowers colonic pH, shifting the NH3/NH4+ equilibrium toward ammonium, which is poorly absorbed and expelled in stool. The secondary mechanism is the cathartic effect itself: by accelerating colonic transit, lactulose reduces the residence time of ingested protein and shed epithelial cells in the colon — limiting the opportunity for urease-producing bacteria to generate ammonia from these nitrogen sources. Less contact time means less ammonia produced, less available for absorption, and faster expulsion of both ammonium and unprocessed nitrogenous material. Together, these mechanisms make lactulose more effective than either mechanism alone, and the two-to-three daily bowel movements target ensures the cathartic component is operating effectively.

Correct Answer

C — Pioglitazone is a PPAR-gamma agonist that improves insulin sensitivity in adipose tissue and liver, reducing hepatic fat delivery from adipocytes and decreasing de novo lipogenesis

Rationale

Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a nuclear receptor expressed predominantly in adipose tissue. PPAR-gamma activation promotes adipocyte differentiation and increases adiponectin secretion, improving insulin sensitivity in both adipose tissue and the liver. Improved insulin sensitivity reduces lipolysis from adipose tissue (decreasing the free fatty acid flux to the liver) and reduces hepatic de novo lipogenesis, together lowering hepatic triglyceride content. In the PIVENS trial, pioglitazone improved hepatic steatosis, inflammation, and hepatocyte ballooning in MASH patients with and without diabetes. Its adverse effects — weight gain (1 to 4 kg), peripheral edema, fluid retention, and a small increase in bladder cancer and heart failure risk — must be weighed against hepatic benefit. It is recommended for MASH patients with type 2 diabetes, where the metabolic benefit is most direct.

Correct Answer

B — A large randomized controlled trial showed that UDCA at 28 to 30 mg/kg/day was associated with worse outcomes including higher rates of liver transplantation and death compared with placebo in PSC patients

Rationale

The evidence against high-dose UDCA in PSC comes from a large randomized controlled trial (Lindor et al., 2009) that tested UDCA at 28 to 30 mg/kg/day versus placebo in 150 PSC patients over 5 years. Rather than showing benefit, the trial was stopped early because the high-dose UDCA group had significantly worse outcomes: higher rates of the composite endpoint of death, liver transplantation, development of varices, cholangiocarcinoma, and disease progression. The mechanism of harm is not fully established but may involve conversion of UDCA to toxic metabolites at high doses in the context of PSC's abnormal bile acid circulation, or direct toxicity at supraphysiological hepatic concentrations. Standard-dose UDCA (13 to 15 mg/kg/day) improves liver biochemistry in PSC but has not shown improvement in transplant-free survival and is used inconsistently across guidelines. UDCA is not recommended at high doses in PSC and should not be used at the same doses validated in PBC.

Correct Answer

D — GLP-1 receptors expressed in hepatocytes directly reduce de novo lipogenesis and improve hepatic insulin signaling, contributing to hepatic fat reduction beyond what weight loss alone explains

Rationale

GLP-1 receptor agonists improve MASH histology through two complementary mechanisms. The primary mechanism is weight loss — sustained 10 to 15 percent body weight reduction with agents like semaglutide reliably reduces hepatic fat content and MASH activity scores. However, controlled analyses and mechanistic studies suggest a direct hepatic component as well: GLP-1 receptors are expressed on hepatocytes, and GLP-1 receptor agonism in the liver reduces de novo lipogenesis (the pathway that converts excess carbohydrates to fatty acids) and improves hepatic insulin sensitivity, reducing the lipid accumulation that drives MASH independent of body weight changes. The ESSENCE trial of semaglutide in MASH showed significant rates of MASH resolution and fibrosis improvement. GLP-1 receptor agonists are not yet specifically approved for MASH as a hepatic indication but are increasingly used in patients who also have type 2 diabetes or obesity.

Correct Answer

A — A Lille score above 0.45 at day 7 identifies non-responders with poor prognosis despite continued prednisolone; the drug should be stopped and patients evaluated for liver transplantation

Rationale

The Lille model is a validated day-7 response assessment tool for prednisolone therapy in severe alcoholic hepatitis, incorporating baseline bilirubin, day-7 bilirubin, and other clinical variables. A Lille score above 0.45 identifies patients whose bilirubin has not improved sufficiently by day 7 despite prednisolone — the non-responder group with a 6-month survival below 25 percent. In these patients, continuing prednisolone beyond day 7 provides no additional benefit while accumulating immunosuppression-related harms (infection, gastrointestinal bleeding). The appropriate action is discontinuation of prednisolone and, in carefully selected patients who are otherwise candidates, early liver transplantation evaluation — which has been performed successfully in well-selected non-responders at specialized centers with carefully designed protocols. A Lille score below 0.45 identifies responders, in whom prednisolone is continued for the full 28-day course.

Correct Answer

B — Exclude active infection before starting prednisolone — immunosuppression in the presence of active bacterial infection substantially worsens outcomes and must be ruled out first

Rationale

A Maddrey discriminant function of 44 clearly meets the threshold for prednisolone (≥32), but initiating corticosteroid therapy before infection is excluded is a patient safety error. Active infection — particularly spontaneous bacterial peritonitis, urinary tract infection, or occult sepsis — is a contraindication to starting prednisolone in severe alcoholic hepatitis. Immunosuppression in the presence of active infection substantially worsens short-term mortality, potentially offsetting or reversing the survival benefit that prednisolone provides in the absence of infection. The correct sequence is: (1) exclude infection by obtaining blood cultures, urinalysis, and if ascites is present, diagnostic paracentesis; (2) screen for hepatitis B (another contraindication due to reactivation risk); (3) once infection and HBV co-infection are excluded, start prednisolone 40 mg daily. The fever present in this patient makes infection screening even more essential before immunosuppression is begun.

Correct Answer

C — Pruritus — obeticholic acid causes pruritus in the majority of patients; proactive management with cholestyramine and dose titration starting at 5 mg reduces this limiting adverse effect

Rationale

Pruritus is the principal dose-limiting adverse effect of obeticholic acid, occurring in the majority of treated patients and leading to dose reduction or discontinuation in a significant proportion. Cholestatic pruritus is already common in PBC, and obeticholic acid can intensify it through its bile acid-related signaling effects on cutaneous itch receptors. Proactive management strategies include: starting at 5 mg daily (titrating to 10 mg after 3 months if tolerated), prescribing cholestyramine as a bile acid sequestrant antipruritic (taken separately from obeticholic acid to avoid binding the drug), and considering rifampicin as an alternative antipruritic for refractory cases. Obeticholic acid is contraindicated in decompensated cirrhosis (Child-Pugh B or C) — this patient has no evidence of decompensation — because it can worsen hepatic function in that setting, but this is a patient selection issue, not the main monitoring point in a compensated patient starting the drug.

Correct Answer

D — Rifaximin — minimally absorbed rifamycin antibiotic that reduces HE hospitalization rates when added to lactulose, with a favorable adverse effect profile supporting long-term secondary prophylaxis

Rationale

After a second episode of overt hepatic encephalopathy, secondary prophylaxis with rifaximin added to lactulose is the evidence-based standard of care. The pivotal trial (Bass et al., N Engl J Med 2010) demonstrated that rifaximin 550 mg twice daily added to lactulose significantly reduced the risk of breakthrough HE episodes and hospitalization compared with lactulose alone. Rifaximin's minimal systemic absorption confines its antibacterial activity to the gut lumen, suppressing ammonia-producing bacteria without the cumulative nephrotoxicity (neomycin) or peripheral neuropathy and disulfiram-like reactions (metronidazole) that limit long-term use of alternative antibiotics. This patient has already had two episodes, making the benefit of recurrence prevention clearly established. Rifaximin is recommended indefinitely for secondary prophylaxis in patients who have recovered from an overt HE episode.

Correct Answer

A — Resmetirom activates thyroid hormone receptor-beta in hepatocytes, stimulating fatty acid oxidation and reducing triglyceride synthesis; cardiac effects are mediated by THR-alpha which resmetirom preferentially spares

Rationale

The pharmacological rationale for resmetirom exploits receptor subtype distribution. Thyroid hormone stimulates hepatic fatty acid oxidation and reduces triglyceride synthesis — effects that would be highly beneficial in MASH. However, systemic thyroid hormone causes cardiac adverse effects (tachycardia, increased cardiac oxygen demand, arrhythmia) through thyroid hormone receptor-alpha (THR-alpha), which predominates in cardiac muscle. Resmetirom was engineered with two layers of selectivity: (1) liver-first pharmacokinetic targeting through hepatic uptake transporters that concentrate the drug in hepatocytes; (2) THR-beta receptor selectivity, preferentially engaging THR-beta (which predominates in hepatocytes and drives the metabolic effects) over THR-alpha (which mediates cardiac effects). This combination produces meaningful hepatic fat reduction and MASH resolution without clinically significant cardiac stimulation. In the MAESTRO-MASH phase 3 trial, resmetirom at 80 or 100 mg daily achieved MASH resolution without fibrosis worsening and fibrosis stage improvement significantly more often than placebo.